CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
pembrolizumabdrug
Likely dose
pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02875132
NCT02875132Phase 2Completed
CompareCT.gov

An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma

Chinese University of Hong Kong·interventional·Posted Aug 23, 2016·Updated Apr 18, 2025

In Brief

A Phase 2 clinical trial evaluating pembrolizumab for Acral Lentiginous Melanoma. Completed, enrolled 9 participants across 1 site.

Detailed Summary

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcral Lentiginous Melanoma
CountriesHong Kong
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 23, 2016
Enrollment StartFeb 15, 2017
Primary CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.9 years ago

Interventions

pembrolizumabdrug

pembrolizumab at 200mg IV infusion every 3 weeks